126 related articles for article (PubMed ID: 36502883)
1. Repression of miR-146a in predicting poor treatment outcome in triple-negative breast cancer.
Panoutsopoulou K; Liu Y; Avgeris M; Dreyer T; Dorn J; Magdolen V; Scorilas A
Clin Biochem; 2023 Apr; 114():43-51. PubMed ID: 36502883
[TBL] [Abstract][Full Text] [Related]
2. A panel of eight microRNAs is a good predictive parameter for triple-negative breast cancer relapse.
Hong HC; Chuang CH; Huang WC; Weng SL; Chen CH; Chang KH; Liao KW; Huang HD
Theranostics; 2020; 10(19):8771-8789. PubMed ID: 32754277
[No Abstract] [Full Text] [Related]
3. A serum microRNA signature predicts tumor relapse and survival in triple-negative breast cancer patients.
Kleivi Sahlberg K; Bottai G; Naume B; Burwinkel B; Calin GA; Børresen-Dale AL; Santarpia L
Clin Cancer Res; 2015 Mar; 21(5):1207-14. PubMed ID: 25547678
[TBL] [Abstract][Full Text] [Related]
4. miR-181a overexpression predicts the poor treatment response and early-progression of serous ovarian cancer patients.
Panoutsopoulou K; Avgeris M; Magkou P; Mavridis K; Dreyer T; Dorn J; Obermayr E; Reinthaller A; Michaelidou K; Mahner S; Vergote I; Loverix L; Braicu I; Sehouli J; Zeillinger R; Magdolen V; Scorilas A
Int J Cancer; 2020 Dec; 147(12):3560-3573. PubMed ID: 32621752
[TBL] [Abstract][Full Text] [Related]
5. miR-629-3p may serve as a novel biomarker and potential therapeutic target for lung metastases of triple-negative breast cancer.
Wang J; Song C; Tang H; Zhang C; Tang J; Li X; Chen B; Xie X
Breast Cancer Res; 2017 Jun; 19(1):72. PubMed ID: 28629464
[TBL] [Abstract][Full Text] [Related]
6. A panel of miRNAs as prognostic markers for African-American patients with triple negative breast cancer.
Turkistani S; Sugita BM; Fadda P; Marchi R; Afsari A; Naab T; Apprey V; Copeland RL; Campbell MC; Cavalli LR; Kanaan Y
BMC Cancer; 2021 Jul; 21(1):861. PubMed ID: 34315420
[TBL] [Abstract][Full Text] [Related]
7. Dysregulation of microRNAs in triple-negative breast cancer.
Paszek S; Gabło N; Barnaś E; Szybka M; Morawiec J; Kołacińska A; Zawlik I
Ginekol Pol; 2017; 88(10):530-536. PubMed ID: 29192413
[TBL] [Abstract][Full Text] [Related]
8. A subgroup of microRNAs defines PTEN-deficient, triple-negative breast cancer patients with poorest prognosis and alterations in RB1, MYC, and Wnt signaling.
Wang DY; Gendoo DMA; Ben-David Y; Woodgett JR; Zacksenhaus E
Breast Cancer Res; 2019 Jan; 21(1):18. PubMed ID: 30704524
[TBL] [Abstract][Full Text] [Related]
9. microRNA expression profiling identifies a four microRNA signature as a novel diagnostic and prognostic biomarker in triple negative breast cancers.
Gasparini P; Cascione L; Fassan M; Lovat F; Guler G; Balci S; Irkkan C; Morrison C; Croce CM; Shapiro CL; Huebner K
Oncotarget; 2014 Mar; 5(5):1174-84. PubMed ID: 24632568
[TBL] [Abstract][Full Text] [Related]
10. miR-146a and miR-638 in BRCA1-deficient triple negative breast cancer tumors, as potential biomarkers for improved overall survival.
Zavala V; Pérez-Moreno E; Tapia T; Camus M; Carvallo P
Cancer Biomark; 2016; 16(1):99-107. PubMed ID: 26835710
[TBL] [Abstract][Full Text] [Related]
11. Clinical Identification of Dysregulated Circulating microRNAs and Their Implication in Drug Response in Triple Negative Breast Cancer (TNBC) by Target Gene Network and Meta-Analysis.
Qattan A; Al-Tweigeri T; Alkhayal W; Suleman K; Tulbah A; Amer S
Genes (Basel); 2021 Apr; 12(4):. PubMed ID: 33918859
[TBL] [Abstract][Full Text] [Related]
12. MicroRNA profiling implies new markers of chemoresistance of triple-negative breast cancer.
Ouyang M; Li Y; Ye S; Ma J; Lu L; Lv W; Chang G; Li X; Li Q; Wang S; Wang W
PLoS One; 2014; 9(5):e96228. PubMed ID: 24788655
[TBL] [Abstract][Full Text] [Related]
13. Low Expression of Circulating MicroRNA-34c is Associated with Poor Prognosis in Triple-Negative Breast Cancer.
Zeng Z; Chen X; Zhu D; Luo Z; Yang M
Yonsei Med J; 2017 Jul; 58(4):697-702. PubMed ID: 28540980
[TBL] [Abstract][Full Text] [Related]
14. miR-105/93-3p promotes chemoresistance and circulating miR-105/93-3p acts as a diagnostic biomarker for triple negative breast cancer.
Li HY; Liang JL; Kuo YL; Lee HH; Calkins MJ; Chang HT; Lin FC; Chen YC; Hsu TI; Hsiao M; Ger LP; Lu PJ
Breast Cancer Res; 2017 Dec; 19(1):133. PubMed ID: 29258605
[TBL] [Abstract][Full Text] [Related]
15. MicroRNAs expression in triple negative vs non triple negative breast cancer in Tunisia: interaction with clinical outcome.
Medimegh I; Omrane I; Privat M; Uhrhummer N; Ayari H; Belaiba F; Benayed F; Benromdhan K; Mader S; Bignon IJ; Elgaaied AB
PLoS One; 2014; 9(11):e111877. PubMed ID: 25369070
[TBL] [Abstract][Full Text] [Related]
16. A prognostic model of triple-negative breast cancer based on miR-27b-3p and node status.
Shen S; Sun Q; Liang Z; Cui X; Ren X; Chen H; Zhang X; Zhou Y
PLoS One; 2014; 9(6):e100664. PubMed ID: 24945253
[TBL] [Abstract][Full Text] [Related]
17. Overexpression of MiR-146a-5p Upregulates lncRNA HOTAIR in Triple-Negative Breast Cancer Cells and Predicts Poor Prognosis.
Liang H; Huang W; Wang Y; Ding L; Zeng L
Technol Cancer Res Treat; 2019; 18():1533033819882949. PubMed ID: 31672084
[TBL] [Abstract][Full Text] [Related]
18. MiR-128 regulation of glucose metabolism and cell proliferation in triple-negative breast cancer.
Xiao M; Lou C; Xiao H; Yang Y; Cai X; Li C; Jia S; Huang Y
Br J Surg; 2018 Jan; 105(1):75-85. PubMed ID: 29116653
[TBL] [Abstract][Full Text] [Related]
19. miR-17-5p suppresses cell proliferation and invasion by targeting ETV1 in triple-negative breast cancer.
Li J; Lai Y; Ma J; Liu Y; Bi J; Zhang L; Chen L; Yao C; Lv W; Chang G; Wang S; Ouyang M; Wang W
BMC Cancer; 2017 Nov; 17(1):745. PubMed ID: 29126392
[TBL] [Abstract][Full Text] [Related]
20. miRNA-135b Contributes to
Uva P; Cossu-Rocca P; Loi F; Pira G; Murgia L; Orrù S; Floris M; Muroni MR; Sanges F; Carru C; Angius A; De Miglio MR
Int J Med Sci; 2018; 15(6):536-548. PubMed ID: 29725243
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
